AZN stock forecast, quote, news & analysis

Key Takeaways

• AstraZeneca reported FY 2025 total revenue of $58.7 billion, up 8% at CER, driven by strong oncology sales.
• Q4 core EPS of $2.12 missed estimates slightly, but shares rose on upbeat 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth.
• Recent partnerships, including a $1.2 billion upfront deal with CSPC for obesity programs, bolster pipeline diversity.
• Stock has gained over 12% YTD, trading near 52-week highs around $204, reflecting investor confidence in long-term targets like $80 billion revenue by 2030.
• Analysts maintain a consensus "Buy" rating, with recent UBS upgrade to Buy underscoring pipeline strength.

Current Market Snapshot

AstraZeneca's stock has shown resilience in recent trading sessions, climbing toward its 52-week high amid robust demand for its oncology portfolio. The shares have outperformed broader indices year-to-date, supported by full-year results that highlighted sustained revenue growth and pipeline advancements. Investor sentiment remains positive, buoyed by strategic expansions into high-growth areas like obesity and continued investments in key markets such as China and the US. While macroeconomic pressures like pricing reforms linger, the company's diversified revenue streams and innovation focus have driven steady appreciation in recent weeks.

Trending AI Robots

Tickeron's Trending AI Robots page highlights the platform's most promising AI-powered trading bots, selected by advanced AI analysis from hundreds of available bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies including technical and fundamental analysis, operating on 5-, 15-, and 60-minute timeframes for day trading, swing trading, and more, with options for low, medium, or high volatility conditions. Powered by over 100 back-tested, forward-tested, and brokerage-tested algorithms, standout performers have delivered annualized returns exceeding 100% in sectors like technology and industrials, with win rates often above 70% and profit factors over 4.0 in top agents. Signal Agents provide real-time alerts for copy trading, Virtual Agents incorporate risk management, and Brokerage Agents use tick-level data. This curated section spotlights bots best suited to current market dynamics, helping traders identify high-probability opportunities. Explore the Trending AI Robots to select and follow top performers tailored to your style.

Recent Developments Driving AZN Price Action

AstraZeneca's stock has surged in recent weeks, gaining over 12% year-to-date and hitting new 52-week highs near $205, fueled by a series of pivotal announcements and solid full-year results. On February 10, the company released FY 2025 results, reporting total revenue of $58.7 billion, up 8% at constant exchange rates (CER), with product sales rising 9%. Oncology remained the growth engine, contributing double-digit increases, while Q4 revenue hit $15.5 billion, up 2% CER, though core EPS of $2.12 slightly missed expectations of $2.18. Despite the miss, shares jumped as management issued 2026 guidance for mid-to-high single-digit total revenue growth and low double-digit core EPS expansion at CER, alongside reaffirmation of the $80 billion revenue ambition by 2030.

Pipeline momentum added tailwinds. On February 3, AstraZeneca and Daiichi Sankyo's Datroway (likely Enhertu) sBLA received FDA priority review for metastatic triple-negative breast cancer, while Saphnelo subcutaneous faced a CRL but maintained sales outlook. Imfinzi's perioperative regimen earned positive CHMP opinion in the EU for gastric cancers on February 2. These oncology updates reinforced the division's dominance, which drove Q4 beats and lifted sentiment.

Strategic moves amplified optimism. Late January saw a landmark collaboration with CSPC Pharmaceuticals: $1.2 billion upfront for ex-China rights to eight obesity/type 2 diabetes programs, including AI-designed peptides and once-monthly injectables, with up to $3.5 billion in milestones—expanding beyond core oncology into booming metabolic spaces. Days earlier, on January 29, AstraZeneca pledged $15 billion in China through 2030 for R&D and manufacturing, building on the Gracell acquisition, signaling commitment to the world's second-largest pharma market amid its NYSE listing debut.

Analyst actions supported the rally. UBS upgraded to Buy on February 13, citing pipeline strength; Citi reiterated Buy with £170 target; Deutsche Bank raised to 11,500 GBp. Consensus leans "Buy," with targets implying upside. Macro factors like US pricing pressures were noted but offset by cancer demand and new launches. Price action linked directly: post-earnings surge on guidance, earlier lifts from China/obesity news, culminating in multi-day gains.

2026 Outlook and Key Factors to Monitor

AstraZeneca enters 2026 with momentum from its oncology franchise and expanding pipeline, guiding mid-to-high single-digit total revenue growth and low double-digit core EPS rise at CER, with a core tax rate of 18-22%. The company targets mid-30s% core operating margins, supported by over 100 Phase 3 trials and 20+ key readouts expected, spanning cancer, rare diseases, and immunology assets like Enhertu, Imfinzi, and new launches in obesity via CSPC. Investments in China ($15 billion through 2030) and US manufacturing will drive localization and innovation in cell therapies, ADCs, and AI-enabled discovery.

Investors should track pipeline milestones, including Datroway priority review outcomes and Saphnelo resubmission, alongside regulatory progress in EU/China. Patent cliffs for legacy drugs pose risks, balanced by $80 billion 2030 revenue goal. US pricing reforms and forex volatility warrant attention, as does competitive dynamics in obesity/metabolics. Oncology demand, new approvals (e.g., Wainua, Koselugo), and M&A like Modella AI integration could sustain growth, while monitoring R&D spend amid margin goals remains key for balanced execution.